GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16-21% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and β-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [52]
Citations
Cites
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In type 2 diabetes, the incretin effect is impaired (2,3), but it remains controversial to what extent the defect is caused by a reduced release of incretin hormones and whether this reduction occurs prior to the development of type 2 diabetes.”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Gender differences in insulin resistance, body composition, and energy balance
Geer, E. B., & Shen, W. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.002 · Cited by 913
Seltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883 · cited 4×
“These findings are in agreement with the glucoregulatory effects of GLP-1 (33,34) and with studies showing that infusion of the GLP-1 receptor antagonist exendin-(9-39) reduced first-phase insulin release and decreased insulin action in healthy individuals and in patients with type 2 diabetes (35,36).”
BackgroundMethodResultInfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide contribute to glucose-stimulated insulin release and therefore play important roles in maintaining normal glucose regulation (1).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Validation of the insulin sensitivity index (ISI0,120): comparison with other measures
Gutt, M., Davis, C. L., Spitzer, S. B., Llabre, M. M., Kumar, M., Czarnecki, E. M., Schneiderman, N., Skyler, J. S., & Marks, J. B. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00116-3 · Cited by 474
Cited by
Items 101–200 of 325
Becetti, I., Bwenyi, E. L., de Araújo, I. E., Ard, J. D., Cryan, J. F., Farooqi, I. S., Ferrario, C. R., Gluck, M. E., Holsen, L. M., Kenny, P. J., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.003 · Cited by 29
Yeow, T. P., Pacini, G., Tura, A., Hor, C. P., Lim, S. L., Tan, F. H. S., Tong, C. V., Hong, J. Y. H., Zain, F. M., Holst, J. J., et al. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000352 · Cited by 26
Self-citationStimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside
Islam, M. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_37 · Cited by 26
Immunometabolic Regulation of Vascular Redox State: The Role of Adipose Tissue
Oikonomou, E. K., & Antoniades, C. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7017 · Cited by 27
“Finally, weight loss per se can improve glycemic and in particular GLP-1 (glucagon-like peptide 1) responses (57,84), which may have a beneficial effect on endothelial oxidative stress (72).”
Cree‐Green, M., Xie, D., Rahat, H., Garcia‐Reyes, Y., Bergman, B. C., Scherzinger, A. L., Behn, C. D., Chan, C. L., Kelsey, M. M., Pyle, L., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00041 · Cited by 29
The Role of Sexual Hormones on the Enteroinsular Axis
Handgraaf, S., & Philippé, J. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00004 · Cited by 26
Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects
Pham, H., Marathe, C. S., Phillips, L. K., Trahair, L. G., Hatzinikolas, S., Huynh, L. Q., Wu, T., Nauck, M. A., Rayner, C. K., Horowitz, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01262 · Cited by 25
Wang, Y. Y., Wang, Y., Qi, X.-Y., Liao, Z., Mai, Y.-N., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839849 · Cited by 30
Incretin Hypersecretion in Gestational Diabetes Mellitus
Fritsche, L., Heni, M., Eckstein, S. S., Hummel, J., Schürmann, A., Häring, H., Preissl, H. T., Birkenfeld, A. L., Peter, A., Fritsche, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac095 · Cited by 27
Yang, Q., Huang, G., Tian, Q., Liu, W., Sun, X., Li, N., Sun, S., Zhou, T., Wu, N., Wei, Y., et al. (2018) · Medicine · doi:10.1097/md.0000000000009943 · Cited by 28
Janus, C., Vistisen, D., Amadid, H., Witte, D. R., Lauritzen, T., Brage, S., Bjerregaard, A., Hansen, T. F., Holst, J. J., Jørgensen, M. E., et al. (2019) · Endocrine Connections · doi:10.1530/ec-19-0408 · Cited by 24
Self-citationGPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion
Chepurny, O. G., Holz, G. G., Roe, M. W., & Leech, C. A. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1306 · Cited by 24
State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis
Wang, L., Savani, R. H., Lu, Y., Bernabucci, M., Luis-Islas, J., Park, E., Singh, I., Xu, W., Ouaamari, A. E., Wheeler, M. B., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01305-x · Cited by 23
“Therefore, we speculate endogenous GLP-1 production or release in DIO is defective, consistent with a previous report demonstrating reductions in oral glucose-induced GLP-1 release in patients with obesity 58 .”
Alterations in GLP-1 and PYY release with aging and body mass in the human gut
Jones, L. A., Sun, E. W. L., Lumsden, A. L., Thorpe, D. W., Peterson, R. A., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112072 · Cited by 25
Vasto, S., Amato, A., Proia, P., & Baldassano, S. (2022) · Biology · doi:10.3390/biology11020296 · Cited by 25
“Physical exercise is indispensable to improve bone health [14,15] and glucose metabolism [16,17].”
BackgroundPhilosophical determinants of obesity as a disease
Kilov, D., & Kilov, G. (2017) · Obesity Reviews · doi:10.1111/obr.12597 · Cited by 24
“In addition, secretion of glucagon-like peptide-1 (GLP-1), an important satiety hormone (18), is attenuated in obesity, with higher GLP-1 responses associated with a lesser degree of obesity (19).”
BackgroundCirculating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women
Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y. (2021) · Nutrients · doi:10.3390/nu13030865 · Cited by 21
“In addition, fasting levels of plasma GLP-1 were significantly higher in patients with T2D than people with normal glucose tolerance (NGT), but the postprandial plasma GLP-1 area under curve was significantly lower in patients with T2D than people with NGT [11,14].”
BackgroundInfluentialGlucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Self-citationThe Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell
Brubaker, P. L. (2022) · Endocrinology · doi:10.1210/endocr/bqac159 · Cited by 23
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Tura, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., Vilsbøll, T., & Mari, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.006 · Cited by 24
Self-citationHorton, W. B., Jahn, L. A., Hartline, L. M., Aylor, K. W., Patrie, J. T., & Barrett, E. J. (2021) · The Journal of Physiology · doi:10.1113/jp281286 · Cited by 20
“In contrast, mixed meal ingestion (Alsalim et al. 2015) and oral glucose (Faerch et al. 2015) stimulate incretin and islet hormone release in healthy humans.”
BackgroundEnteroendocrine System and Gut Barrier in Metabolic Disorders
Osinski, C., Moret, D., Clément, K., Serradas, P., & Ribeiro, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073732 · Cited by 22
Ahmad, M. A., Karavetian, M., Moubareck, C. A., Wazz, G., Mahdy, T., & Venema, K. (2022) · Nutrients · doi:10.3390/nu14061271 · Cited by 22
“blood glucose levels, hunger, and energy consumption has been proven effective in recent studies [43,44].”
Nguyen, N. Q., Debreceni, T. L., Burgess, J. E., Bellon, M., Wishart, J. M., Standfield, S., Malbert, C., & Horowitz, M. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0012-6 · Cited by 22
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
Dirksen, C., Graff, J., Fuglsang, S., Rehfeld, J. F., Holst, J. J., & Madsen, J. L. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00310.2018 · Cited by 19
Self-citationGlucose Counter-regulation After Acute Pancreatitis
Bharmal, S. H., Pendharkar, S. A., Singh, R. G., Cho, J., & Petrov, M. S. (2019) · Pancreas · doi:10.1097/mpa.0000000000001318 · Cited by 19
Nagahisa, T., Yamaguchi, S., Kosugi, S., Homma, K., Miyashita, K., Irie, J., Yoshino, J., & Itoh, H. (2022) · Endocrinology · doi:10.1210/endocr/bqac023 · Cited by 20
Foghsgaard, S., Vedtofte, L., Andreasen, C. H., Andersen, E. S., Bahne, E., Bagger, J. I., Svare, J., Holst, J. J., Clausen, T. D., Mathiesen, E. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4265-8 · Cited by 19
Self-citationA role for methanogens and methane in the regulation of GLP ‐1
Laverdure, R., Mezouari, A., Carson, M. A., Basiliko, N., & Gagnon, J. (2017) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.6 · Cited by 19
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationWatkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 23
Self-citationNutrient Combinations Sensed by L-Cell Receptors Potentiate GLP-1 Secretion
Sodum, N., Mattila, O., Sharma, R., Kamakura, R., Lehto, V., Walkowiak, J., Herzig, K., & Raza, G. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021087 · Cited by 21
“In insulin resistance, GLP-1 secretion is impaired [20–23].”
BackgroundPAGE, L. C., & Freemark, M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00409-7 · Cited by 19
Ruetten, H., Gebauer, M., Raymond, R. H., Calle, R. A., Cobelli, C., Ghosh, A., Robertson, R. P., Shankar, S. S., Staten, M. A., Stefanovski, D., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0022 · Cited by 17
Suvan, J. E., Masi, S., Harrington, Z., Santini, E., Raggi, F., D’Aiuto, F., & Solini, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa757 · Cited by 19
Smith, K., Taylor, G., Allerton, D. M., Brunsgaard, L. H., Davies, K. A. B., Stevenson, E., & West, D. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.696977 · Cited by 18
The protective effects of lipoxin A4 on type 2 diabetes mellitus: A Chinese prospective cohort study
Wang, S., Qian, X., Shen, C., Sun, Q., Jing, Y., Liu, B., Zhang, K., Li, M., Wang, J., Zhou, H., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1109747 · Cited by 20
Koopman, A. D. M., Rutters, F., Rauh, S. P., Nijpels, G., Holst, J. J., Beulens, J. W. J., Alssema, M., & Dekker, J. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191114 · Cited by 17
Self-citationProceedings of the 2017 ASPEN Research Workshop—Gastric Bypass: Role of the Gut
Jain, A. K., le Roux, C. W., Puri, P., Tavakkoli, A., Gletsu-Miller, N. A., Laferrère, B., Kellermayer, R., DiBaise, J. K., Martindale, R. G., & Wolfe, B. M. (2018) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1121 · Cited by 19
GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
Kumar, V. (2025) · Open Biology · doi:10.1098/rsob.240303 · Cited by 18
Ebbesen, M., Kissow, H., Hartmann, B., Grell, K., Gørløv, J. S., Kielsen, K., Holst, J. J., & Müller, K. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.036 · Cited by 16
Self-citationAsmar, A., Cramon, P. K., Asmar, M., Simonsen, L., Sørensen, C. M., Madsbad, S., Moro, C., Hartmann, B., Rehfeld, J. F., Holst, J. J., et al. (2020) · Physiological Reports · doi:10.14814/phy2.14519 · Cited by 18
Self-citationHealth Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
Spinelli, K. J., Oakes, A. H., Chiu, S., Imboden, M. T., Miller, A. B., Jain, S., & Gluckman, T. J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100100 · Cited by 16
Meek, C. L., Lewis, H. B., Burling, K., Reimann, F., & Gribble, F. M. (2020) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563220975658 · Cited by 19
Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
Jujić, A., Godina, C., Belting, M., Melander, O., Holst, J. J., Ahlqvist, E., Gomez, M. F., Nilsson, P. M., Jernström, H., & Magnusson, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-27509-3 · Cited by 15
Self-citationGulati, S., Misra, A., Tiwari, R., Sharma, M., Pandey, R. M., Upadhyay, A. D., & Sati, H. C. (2023) · European Journal of Clinical Nutrition · doi:10.1038/s41430-023-01263-1 · Cited by 18
“Individuals with prediabetes and T2D demonstrate lower GLP-1 response to an oral glucose load in comparison to healthy individuals [38].”
BackgroundSukumar, N., Bagias, C., Goljan, I., Ghebremichael‐Weldeselassie, Y., Gharanei, S., Tan, B. K., Holst, J. J., & Saravanan, P. (2018) · Diabetes · doi:10.2337/db18-0254 · Cited by 15
Self-citationYunker, A. G., LUO, S. H., Jones, S., Dorton, H. M., Alves, J. M., ANGELO, B. C., DEFENDIS, A. W., Pickering, T. A., Monterosso, J. R., & Page, K. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa865 · Cited by 17
Wang, X., Chen, C., Xie, C., Huang, W., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., Sun, Z., & Wu, T. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14683 · Cited by 15
Sex differences feed into nuclear receptor signaling along the digestive tract
Dean, A. E., Reichardt, F., & Anakk, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166211 · Cited by 17
Nagahisa, T., Kosugi, S., & Yamaguchi, S. (2023) · Nutrients · doi:10.3390/nu15061494 · Cited by 15
Stefanakis, K., Kokkinos, A. D., Simati, S., Argyrakopoulou, G., Konstantinidou, S. M., Kouvari, M., Kumar, A., Kalra, B., & Mantzoros, C. S. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.026 · Cited by 14
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor
Lin, L., Pan, X., Feng, Y., & Yang, J. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241252309 · Cited by 16
Deli, C. K., Fatouros, I. G., Poulios, A., Liakou, C. A., Draganidis, D., Παπανικολάου, Κ., Rosvoglou, A., Gatsas, A., Georgakouli, K., Tsimeas, P. D., et al. (2024) · Life · doi:10.3390/life14081016 · Cited by 17
“Reduced glucose-stimulated GLP-1 responses have been reported in obese individuals and individuals with pre-D and T2D compared to individuals with NGT [25], suggesting that alterations in GLP-1 release contribute to glucose and appetite dysregulation.”
BackgroundUmapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., Lindquist, P., Silva, P. N., Goga, A., Trüllinger, G. O., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01630-0 · Cited by 15
“We retrospectively examined amidated GLP-1 levels in two Danish Cohorts (AdditionPRO and Family studies – Additional file 1: Table S1) [22, 40].”
Self-citationJones, S., Hyde, A., & Davidson, T. L. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.001 · Cited by 18
Jones, S., LUO, S. H., Dorton, H. M., Yunker, A. G., ANGELO, B. C., DEFENDIS, A. W., Monterosso, J. R., & Page, K. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.638504 · Cited by 16
The role of gut microbiome in prevention, diagnosis and treatment of gestational diabetes mellitus
Tsarna, E., & CHRISTOPOULOS, P. F. (2021) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2021.1959534 · Cited by 14
“Results regarding bdiversity are conflicting, as a significant difference is detected in some studies (Kuang et al. 2017; Liu et al. 2019; Ye et al. 2019; Wu et al. 2020; Xu et al. 2020) but not in others (Koren et al. 2012; Crusell et al. 2018; Ferrocino et al. 2018; Cortez et al. 2019).”
BackgroundInfluentialZhang, Z., Qi, Y., Kong, W., Jin, Q., Wang, X., Dong, Y., Wang, Y., & Li, H. (2018) · Medical Science Monitor · doi:10.12659/msm.911062 · Cited by 14
Fourny, N., Lan, C., Bernard, M., & Desrois, M. (2021) · Nutrients · doi:10.3390/nu13092914 · Cited by 16
“In prediabetic men this relative response does not differ in comparison to healthy men [38].”
ResultLemos, J. R. N., Baidal, D. A., Poggioli, R., Fuenmayor, V., Chavez, C., Alvarez, A., Linetsky, E., Mauvais‐Jarvis, F., Ricordi, C., & Alejandro, R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab787 · Cited by 16
Izaguirre, M., Gómez‐Ambrosi, J., Rodríguez, A., Ramírez, B., Becerril, S., Valentí, V., Moncada, R., Unamuno, X., Silva, C., de la Higuera, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040479 · Cited by 14
“In this sense, a lower GLP-1 response in prediabetic or even obese patients has been previously observed [28].”
ResultLundgren, J. R., Færch, K., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Holst, J. J., Vistisen, D., Jørgensen, M. E., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0937-7 · Cited by 14
Self-citationvan Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Preinfalk, V., Schweiger, K., Galassi, C., Karl, C. M., Treml, J., Ley, J. P., König, J. S., Krammer, G. E., Somoza, V., & Lieder, B. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000472 · Cited by 13
Perakakis, N., Kokkinos, A. D., Angelidi, A. M., Tsilingiris, D., Gavrieli, A., Yannakoulia, M., Tentolouris, N., & Mantzoros, C. S. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.001 · Cited by 13
Stinson, S. E., Alzola, I. F. D. R., Hovendal, E. D. B., Lund, M. A. V., Fonvig, C. E., Holm, L. A., Jonsson, A. E., Frithioff‐Bøjsøe, C., Christiansen, M., Pedersen, O. B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad728 · Cited by 13
“…an OGTT compared with individuals with obesity and normal insulin sensitivity, and controls with NW. Adults with obesity and T2D have lower GLP-1 responses after an oral glucose load than healthy individuals, which associates with worsened insulin sensitivity and impaired β -cell function (38).”
BackgroundSelf-citationHe, W., Mori, M., Yu, X., & Kanda, T. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-015-0168-1 · Cited by 12
Lee, S. A., Koh, G., Cho, S. J., Yoo, S., & Chin, S. O. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.3.439 · Cited by 12
Ferjan, S., Jensterle, M., Oblak, T., Žitnik, I. P., Marc, J., Goričar, K., Dolžan, V., & Janež, A. (2019) · Journal of International Medical Research · doi:10.1177/0300060519865351 · Cited by 12
“Data from comparable previous studies reported a 25% difference in GLP-1 levels between subjects with NGT and subjects with IGT.(7,28) To detect a statistically significant difference in GLP-1 levels Ferjan et al.”
ResultInfluentialThe Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Muscogiuri, G., Caporusso, M., Caruso, P., Poggi, C. D., Vitale, M., Zurru, A., Colao, A., & the Italian Study Group on Gender Difference in Endocrine Diseases (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02491-3 · Cited by 14
“However, regardless of the diagnostic method, some data suggest that females had lower GLP-1 response to a 75-g OGTT than males in the presence of IGT [ 73].”
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Holst, J. J., Pedersen, J., Wewer Albrechtsen, N. J., & Knop, F. K. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0015 · Cited by 11
“11,12 Probably it is of greater importance that the insulinotropic action of both hormones is also impaired.”
Self-citationChong, S. C., Sukor, N., Robert, S. A., Ng, K. F., & Kamaruddin, N. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.961432 · Cited by 13
Rodríguez, R., Moreno, M., Lee, A. Y., Godoy-Lugo, J. A., Nakano, D., Nishiyama, A., Parkes, D. G., Awayda, M. S., & Ortiz, R. M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0070-0 · Cited by 11
Trahair, L. G., Marathe, C. S., Standfield, S., Rayner, C. K., Feinle‐Bisset, C., Horowitz, M., & Jones, K. L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.202 · Cited by 12
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Role of fasting duration and weekday in incretin and glucose regulation
Clemmensen, K. K. B., Quist, J. S., Vistisen, D., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Holst, J. J., Lauritzen, T., Jørgensen, M. E., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0009 · Cited by 12
“The intraassay coefficient of variation was 0.011, and the interassay coefficient of variation was 0.036 with serum insulin levels of 129 pmol/L (18).”
BackgroundInfluentialSelf-citationA High-Throughput Automated Microfluidic Platform for Calcium Imaging of Taste Sensing
Hsiao, Y.-H., Hsu, C., & Chen, C. (2016) · Molecules · doi:10.3390/molecules21070896 · Cited by 10
Chang, K.-J., Lin, J., Chen, S.-Y., Weng, M.-H., & Yen, G. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.03.012 · Cited by 10
Abildgaard, J., Ploug, T., Pedersen, A. T., Eiken, P., Pedersen, B. K., Holst, J. J., Hartmann, B., & Lindegaard, B. (2020) · Bone · doi:10.1016/j.bone.2020.115612 · Cited by 10
Self-citationThe relationship between glucose and the liver-alpha cell axis – A systematic review
Pixner, T., Stummer, N., Schneider, A.-M., Lukas, A., Gramlinger, K., Julian, V., Thivel, D., Mörwald, K., Mangge, H., Dalus, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061682 · Cited by 11
Cordiner, R. L. M., Bedair, K., Mari, A., & Pearson, E. R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae033 · Cited by 9
Theodorakis, M. J. (2015) · Diabetes · doi:10.2337/db15-0614 · Cited by 9
“(1) concluded that glucagon-like peptide 1 (GLP-1) response to oral glucose tolerance testing (OGTT) was up to 25% impaired in prediabetes and screen-detected diabetes compared with normal glucose tolerance (NGT) and more pronounced in women than men.”
BackgroundBrøns, C., Saltbæk, P. N., Friedrichsen, M. H., Chen, Y., & Vaag, A. A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0177 · Cited by 10
Effects of Liver Resection on Hepatic Short-Chain Fatty Acid Metabolism in Humans
Neis, E. P. J. G., Bloemen, J. G., Rensen, S. S., van der Vorst, J. R., van den Broek, M. A. J., Venema, K., Buurman, W. A., & Dejong, C. H. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166161 · Cited by 10
Wang, X., Lv, X., Qi, Y., Wang, S., Yang, M., Wang, B., Cao, H., Zhang, J., & Xu, X. J. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10564-9 · Cited by 11
“It is noteworthy that obese patients generally have impaired glucagon-like peptide-1 (GLP-1) secretion [7, 8].”
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
“Furthermore, an increased GLP-1 production following an oral glucose test in healthy women compared to men has been also reported [128].”
Holt, J., Sandsdal, R. M., Byberg, S., Janus, C., Juhl, C. R., Jørgensen, J. R., Hartmann, B., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2025) · Obesity · doi:10.1002/oby.70043 · Cited by 8
“Obesity seems associated with lowered levels of the appetite-inhibiting hormone glucagon-like peptide-1 (GLP-1) after meals [4], although findings have been inconsistent, especially in rodents [5].”
Self-citationAlvarez-Canales, M. F. D. L. L., Salazar-López, S. S., Farfán-Vázquez, D., Martínez-López, Y. E., González-Mena, J. N., Jiménez-Ceja, L. M., Vargas‐Ortiz, K., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., Folli, F. B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88108-8 · Cited by 8
MCRAE, A. N., Ticho, A. L., Liu, Y., Ricardo-Silgado, M. L., Mangena, N. N., Feris, F., Gonzalez‐Izundegui, D., Calderón, G., Rohakhtar, F. R., Simon, V. A., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105283 · Cited by 8
Gilliam‐Vigh, H., Ellegaard, A., Madsen, M. R., Lund, A., Jensen, B. A. H., Vilsbøll, T., Rigbolt, K. T. G., & Knop, F. K. (2025) · Gut · doi:10.1136/gutjnl-2024-334124 · Cited by 8
“For regions 7, 8 and 9, samples from individuals with T2D approximated the proximal small intestine (regions 4, 5 and 6), while similar samples from their normoglycaemic counterparts clustered closer to the ileocaecal sample (figure 2B).”
le Roux, C. W., Engström, M., Björnfot, N., Fändriks, L., & Docherty, N. G. (2015) · Obesity Surgery · doi:10.1007/s11695-015-2005-z · Cited by 8
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
Torekov, S. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy124 · Cited by 10
Self-citationExenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use
Deeks, E. D. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-018-00597-2 · Cited by 8
Lee, C. Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.748477 · Cited by 10
Gosselé, K. A., Opitz, L., Arnold, M., Simon, E., Neubauer, H., & Wolfrum, S. (2019) · Peptides · doi:10.1016/j.peptides.2019.01.001 · Cited by 8
Kadowaki, T., Lee, S. Y., Ogawa, W., Nishida, T., Overvad, M., Tobe, K., Yamauchi, T., & Lim, S. K. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.002 · Cited by 11
Metadata
- Authors
- Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., & Jørgensen, M. E.
- Affiliations
- Steno Diabetes Center, Gentofte, Denmark
- University of Copenhagen (DK)
- Danish Diabetes Academy (DK)
- Section for General Practice, Department of Public Health, Aarhus, Denmark
- Corresponding author
- Færch, Kristine
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-12
- Volume
- 64
- Issue
- 7
- Pages
- 2513-2525
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2081594150
- Cited by
- 321
- References
- 54
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 28 · 2022: 27 · 2021: 34 · 2020: 28 · 2019: 41 · 2018: 26 · 2017: 20 · 2016: 22 · 2015: 11
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Foundation
- Danish Centre for Evaluation and Health Technology Assessment
- Diabetes Fund of the National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801)
- National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe, and Southern Jutland in Denmark
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, glucose-stimulated insulin secretion, prediabetes, type 2 diabetes, obesity, sex differences, oral glucose tolerance test, insulin sensitivity, beta-cell function
- MeSH terms
- Age Factors, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Obesity, Prediabetic State, Sex Characteristics, Body Mass Index, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.